LFCR — Lifecore Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- $242.60m
- $380.42m
- $128.87m
Annual cashflow statement for Lifecore Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2022 May 29th | 2023 May 28th | 2024 May 26th | 2025 May 25th | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 7 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-KT |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -117 | -99.6 | 12 | -38.7 | -18 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 86 | 48.5 | -17.4 | 35.2 | 22.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.1 | 20 | -3.85 | -4.7 | -3.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22.6 | -17.4 | -0.217 | -0.206 | 7.33 |
| Capital Expenditures | -29.9 | -21.5 | -17.9 | -13.4 | -3.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 110 | 16.7 | 0 | 7 | 10 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 80 | -4.81 | -17.9 | -6.42 | 6.3 |
| Financing Cash Flow Items | -1.61 | -6.32 | 4.62 | -1.71 | -1.93 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -57 | 39.7 | 7.51 | 6.42 | -4.43 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.348 | 17.4 | -10.6 | -0.197 | 9.2 |